The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNFa inhibitor, such as a human TNFa antibody, or antigenbinding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNFa inhibitor for treatment of JRA in a subject.